2322-PUB: Consistency and Predictability of Control of Glycemic Variability with U200 (Concentrated r-DNA Human Insulin Premix 30/70 - 200 IU/mL) in Type 2 Diabetes Mellitus Patients

Abstract

Introduction: In type 2 diabetes mellitus (T2DM) patients, U200 (concentrated r-DNA Human Insulin Premix 30/70 - 200IU/mL) provides good control of glycemic variability with minimal glycemic excursions and substantial time spent in euglycemia. Objective of this subgroup analysis was to assess consistency and predictability of control of glycemic variability with U200 by gender, body mass index (BMI) and daily insulin dose. Methods: Sixty adult patients with T2DM on treatment with human insulin (regular/NPH/Premix) on stable insulin dose were treated with U200 for 7 days. Variability in 24-hour blood glucose profile measured by CGMS device was compared between various subgroups. Results: There was no statistically significant difference between male and female, patients with BMI <25 kg/m2 vs. ≥ 25 kg/m2 and with daily insulin dose < 20 IU vs. ≥ 20 IU for mean blood glucose, mean number and duration of hyperglycemic episodes (>150 mg/dL), mean number and duration of hypoglycemic episodes (<70 mg/dL), and % of time spent in euglycemic range (70 - 150 mg/dL). Conclusion: Mean blood glucose, frequency-duration of excursions and time spent in euglycemic range with U200 were unaffected by gender, BMI and daily insulin dose thereby emphasizing consistency and predictability of control of glycemic variability across a wide range of patients. Disclosure H. Thacker: None. J. Kesavadev: None. S.A. Ingole: Employee; Self; Wockhardt. A. Shah: Employee; Self; Wockhardt. R. Jain: Employee; Self; Wockhardt. Funding Wockhardt Pharmaceuticals Ltd.